Listing 3 - Actual negotiations

Indication:

Conception Control

Indication:

Breast cancer, unresectable locally advanced or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) in adult patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting

Indication:

Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy

Indication:

Acne Vulgaris

Indication:

Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74

Indication:

Epilepsy, partial-onset seizures

Indication:

Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy

Indication:

For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)

Indication:

Multiple Indications

Indication:

Multiple Indications